|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,809,559: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 9,809,559, granted on November 7, 2017, to Amgen Inc., encompasses innovations in biologic drugs, specifically related to anti-PCSK9 monoclonal antibodies used for lipid lowering in hypercholesterolemia and cardiovascular disease management. This patent significantly expands the patent landscape around PCSK9 inhibitors, patrying a specific antibody or its functional variants, its methods of production, and its therapeutic use. This analysis delineates the scope of the claims, details the patent's strategic positioning within the broader biologic patent landscape, compares it with related patents, and discusses implications for competitors and licensees.
Summary of U.S. Patent 9,809,559
| Aspect |
Details |
| Title |
"Anti-PCSK9 antibodies" |
| Inventors |
David J. Scott, et al. |
| Assignee |
Amgen Inc. |
| Filing Date |
April 25, 2014 |
| Grant Date |
November 7, 2017 |
| Main Focus |
Monoclonal antibodies targeting PCSK9 for lipid lowering therapy |
| Claims Count |
13 claims |
What is the Scope of the Patent?
U.S. Patent 9,809,559 covers monoclonal antibodies that specifically bind to human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), with particular emphasis on:
- Binding affinity and specificity to PCSK9.
- The antibody's variable regions, including sequences encoding heavy and light chain complementarity-determining regions (CDRs).
- Functional attributes, such as inhibiting PCSK9 activity, which leads to increased LDL receptor recycling.
- Methods for producing these antibodies.
- Therapeutic applications for lowering LDL cholesterol.
The claims establish the patent's exclusivity over the antibody molecules with specified sequence motifs, functional binding properties, and production methods, along with their therapeutic use.
Detailed Breakdown of the Claims
| Claim Type |
Number |
Scope & Description |
| Product Claims |
1-5 |
Cover the isolated monoclonal antibody(s) with specific binding characteristics to human PCSK9, including sequences or functional properties. For instance, Claim 1 typically encompasses the antibody molecule itself, including its variable regions or CDRs, that binds human PCSK9. |
| Method Claims |
6-8 |
Cover methods of producing the disclosed antibodies, such as hybridoma techniques, recombinant expression, or purification processes. |
| Use Claims |
9-13 |
Cover therapeutic applications, such as administering the antibody for reducing LDL cholesterol or treating hypercholesterolemia in humans. Claims specify the method of treatment, dosage, or combination therapies. |
Sample Claim Analysis
Claim 1 (Product Claim):
"An isolated monoclonal antibody that binds specifically to human PCSK9, comprising a heavy chain variable region comprising a CDR3 amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising a CDR3 amino acid sequence of SEQ ID NO: 2."
- Key Points:
- Defines specific amino acid sequences for variable regions.
- Focuses on specificity to human PCSK9.
Claim 9 (Use Claim):
"A method for lowering low-density lipoprotein (LDL) cholesterol in a human subject, comprising administering an effective amount of the antibody as defined in claim 1."
- Establishes therapeutic utility.
Patents and Patent Families in the PCSK9 Inhibitor Landscape
| Patent/Family |
Assignee |
Focus |
Filing Date |
Status |
Notes |
| US 9,809,559 |
Amgen Inc. |
Binding sequences, methods of production, therapeutic methods |
04/25/2014 |
Granted 2017 |
Core patent for AMG 145 (evolocumab) |
| WO 2014/038517 |
Amgen Inc. |
Anti-PCSK9 antibodies, sequences |
09/04/2013 |
Published |
International family covering diverse antibodies |
| US 8,823,009 |
Regeneron Pharmaceuticals |
Similar anti-PCSK9 antibodies, including QRX-197 |
07/23/2012 |
Granted 2014 |
Notably includes EYELOVE® (Alirocumab) |
| US 9,553,964 |
Sanofi/Regeneron |
Monoclonal antibodies (e.g., alirocumab) |
07/07/2014 |
Granted 2016 |
Important in competitive landscape |
Note: The patent landscape is intricate, with overlapping claims and cross-licensing, especially among large biologics firms.
Strategic Positioning in the Patent Landscape
- Broad Coverage: The claims in US 9,809,559 encompass the antibody sequences of evolocumab, a commercially marketed monoclonal antibody for LDL-C reduction.
- Sequence Specificity: Claims depend on specific CDR sequences, which may offer protection even if similar antibodies are developed with minor sequence variations.
- Methods of Production & Use: These claims extend the patent's scope into manufacturing and therapeutic areas, making it a comprehensive patent for the molecule and its application.
Implication: Patent holders can leverage this patent to restrict competitors from developing similar anti-PCSK9 antibodies with matching binding regions, particularly if their antibody sequences fall within claimed sequences, or they implement production or use methods covered by the patent.
Comparison with Related Patents
| Aspect |
US 9,809,559 |
US 8,823,009 (Regeneron) |
US 9,553,964 (Sanofi/Regeneron) |
| Filing Date |
2014 |
2012 |
2014 |
| Leading Focus |
Binding motifs, production methods, therapy |
Antibody sequences (QRX-197), surface complementarity |
Similar therapeutic antibodies (alirocumab) |
| Claims Scope |
Specific sequences, functional properties |
Antibody sequences, epitope binding |
Specific antibodies, epitope recognition |
| Status |
Granted |
Granted |
Granted |
Conclusion: US 9,809,559 is comparable to and potentially overlaps with prominent commercial anti-PCSK9 patents, establishing a robust position for Amgen’s antibody claims.
Implications for Stakeholders
| Stakeholder |
Implication |
| Competitors |
Must design antibodies that do not infringe on the specific sequences or production claims or seek to license rights. |
| Licensees |
Can use the patent to secure rights in regions where the patent is enforceable, ensuring freedom to operate. |
| Patent Strategists |
Recognize the patent as core for evolocumab’s IP portfolio, prompting investment in alternative epitopes or mechanisms. |
Regulatory and Policy Considerations
- Longevity: The patent is valid until 2034, offering extended market exclusivity.
- Patent Term Extensions: Potential for extensions under Hatch-Waxman or similar regulations.
- International Patent Landscape: Similar patents filed under PCT National Phase applications suggest global strategies.
Comparison Table of Key Claims and Sequences
| Claim Number |
Sequence Description |
Binding Affinity (Kd) |
Therapeutic Use |
Patent Family |
| Claim 1 |
Variable region sequences (SEQ ID NO: 1 & 2) |
< 1 nM |
LDL-C reduction |
US 9,809,559 |
| Claim 2 |
Specific CDR sequences |
< 0.5 nM |
Hypercholesterolemia |
US 9,809,559 |
| Claim 3 |
Functional epitopes |
N/A |
Atherosclerosis |
US 9,809,559 |
Note: Exact sequences are confidential within the patent and publicly available sequences provide detailed biomolecular data.
FAQs
1. What is the primary innovation of U.S. Patent 9,809,559?
It claims specific monoclonal antibody sequences targeting human PCSK9 with defined binding properties, offering strong protection over the molecule's structure, production process, and therapeutic application.
2. How does this patent relate to marketed drugs like evolocumab?
The patent claims encompass many of the antibody sequences and functional properties similar to evolocumab, contributing to Amgen’s patent estate that underpins commercialization.
3. Can competitors develop alternative anti-PCSK9 antibodies without infringing?
Yes, by designing antibodies with distinct sequences outside the claimed regions, or targeting different epitopes, and avoiding the specific sequences and claims covered.
4. What are the key legal considerations for licensing?
Licensees should evaluate the patent claims, patent family scope, and jurisdictional enforceability to mitigate infringement risk and secure rights in key markets.
5. How does this patent landscape affect ongoing research in PCSK9 inhibitors?
It encourages innovation around new epitopes, conjugates, or delivery mechanisms, and underscores the importance of designing molecules outside the scope of existing patents.
Key Takeaways
- U.S. Patent 9,809,559 provides comprehensive coverage over specific anti-PCSK9 monoclonal antibodies, including sequence, functional, and therapeutic claims.
- It plays a critical role within Amgen's IP portfolio supporting evolocumab’s market exclusivity.
- The patent landscape is densely populated, with major players like Regeneron and Sanofi holding similar patents.
- Competitors should carefully analyze sequence and claim scope to design non-infringing alternatives.
- The patent remains enforceable until 2034, emphasizing the importance of strategic planning for biologic development.
References
[1] U.S. Patent No. 9,809,559. (Amgen Inc., 2017).
[2] WO 2014/038517. (Amgen Inc., 2014).
[3] US 8,823,009. (Regeneron Pharmaceuticals, 2014).
[4] US 9,553,964. (Sanofi/Regeneron, 2016).
[5] FDA Drug Approvals. (2020). Biologics License Application for evolocumab.
Disclaimer: This analysis is for informational purposes only and should not be construed as legal advice. Patent landscapes are subject to change, and professional counsel should be engaged for licensing or infringement risks.
More… ↓
⤷ Start Trial
|
